GLAXOSMITHKLINE has confirmed it is currently experiencing an "ongoing supply constraint" of its Engerix-B (hepatitis B surface antigen recombinant (yeast) vaccine) adult in Australia, due to a precautionary halt in the manufacturing process.
The company said production is now back to normal, but it will take time to rebuild capacity and at this stage GSK is unable to confirm a re-supply date.
Engerix-B paediatric dose is still available, with GSK prioritising hepatitis B vaccine availability for those most at risk of infection.
All Australian federal, state and territory government vaccination programs continue to receive an uninterrupted supply of Engerix-B, while the Twinrix combination hepatitis A and B vaccine is also still available, the company confirmed.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Aug 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Aug 17
